MedTrace Logo

A Study to Evaluate the Efficacy and Safety of X0002 Spray in Subjects With Osteoarthritis Knee Pain

NCT03081806 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 399

Last updated 2024-03-28

No results posted yet for this study

Summary

This is a Phase 3, Multicenter, 22-Week, double-blind and 30-Week open label Study to Evaluate the Efficacy and Safety of X0002 Spray in relief of pain of subjects with Osteoarthritis of the Knee.

Conditions

  • Pain Associated With Osteoarthritis of the Knee

Interventions

DRUG

X0002

Subjects will complete 22 weeks of double-blind treatment and then enter into 30 weeks open-label treatment.

Sponsors & Collaborators

  • Techfields Pharma Co. Ltd

    lead INDUSTRY

Principal Investigators

  • Chongxi Yu, PhD · Techfields Inc

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
35 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-24
Primary Completion
2024-01-10
Completion
2024-01-10
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03081806 on ClinicalTrials.gov